Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults

Abstract

GD2/GD3 expression among pediatric solid tumors is common, albeit with variable level of expression. Especially for patients with sarcoma, these gangliosides can be potential targets for antibody-based therapies.